Delenex extends A round, adding $19.2 million

Delenex Therapeutics AG (Zurich, Switzerland) raised CHF16.7 million ($19.2 million) in an extension of a series A round, bringing the total raised in the round to CHF30.2 million ($34.8 million). New investor Novo Ventures led the extension, with participation from existing investors SV Life Sciences; HBM BioCapital; HBM BioVentures; BioMedInvest; and VI Partners. Novo's Thomas Dyrberg will join Delenex's board. ...